Products

PEG-FILGRASTIM 6mg Pen: Long-Acting Hematopoietic Support for Chemotherapy-Induced Neutropenia Are you searching for a reliable PEG-FILGRASTIM 6mg Pen exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced biologic supportive therapies. We maintain an agile and secure supply chain for London (UK), Washington (USA), Canberra (Australia), and South Africa, ensuring that critical oncology medications reach institutional pharmacies with 100% pharmaceutical integrity. Detailed Product Profile: What is PEG-FILGRASTIM 6mg? PEG-FILGRASTIM 6mg is a long-acting, pegylated form of recombinant human granulocyte colony-stimulating factor (G-CSF). Delivered via a convenient Pre-filled Pen (Autoinjector), this biologic medication is designed to stimulate the bone marrow to produce white blood cells (neutrophils). It is essential for patients undergoing myelosuppressive chemotherapy, where the risk of life-threatening infection due to low white blood cell counts is high. 1. Therapeutic Indications Chemotherapy-Induced Neutropenia (CIN): To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs. Hematopoietic Subsyndrome of Acute Radiation Syndrome: To increase survival in patients acutely exposed to myelosuppressive doses of radiation. Supportive Oncology Care: Helping patients maintain their chemotherapy dose intensity and schedule by preventing dangerous drops in absolute neutrophil count (ANC). 2. Mechanism of Action: Sustained White Blood Cell Stimulation Colony Stimulation: It binds to specific surface receptors on hematopoietic cells, stimulating the proliferation, differentiation, and activation of neutrophil precursors. Pegylation Advantage: The addition of polyethylene glycol (PEG) to the filgrastim molecule increases its size and reduces renal clearance. This results in a significantly longer half-life compared to standard filgrastim. Self-Regulating Clearance: The drug is primarily cleared from the body by the very neutrophils it creates. As the neutrophil count rises, the drug level falls, providing a “smart“ dosing effect that lasts the duration of a chemotherapy cycle. 3. Administration and The “Pen“ Advantage Standard Dosing: A single 6mg subcutaneous injection administered once per chemotherapy cycle. Timing: It must be administered at least 24 hours after the last dose of cytotoxic chemotherapy and at least 14 days before the next dose. The Autoinjector Pen: The 6mg Pen formulation offers superior ease of use for home administration, featuring hidden needles and automated delivery to ensure precise dosing and improved patient compliance compared to traditional syringes. Clinical Side Effects & Safety Monitoring Bone Pain: Medullary bone pain is the most common side effect; it is typically mild to moderate and manageable with non-opioid analgesics. Splenic Rupture: Though rare, any pain in the left upper abdomen or shoulder tip must be evaluated immediately. Acute Respiratory Distress Syndrome (ARDS): Monitoring for fever, cough, or shortness of breath. Sickle Cell Crisis: Patients with sickle cell disorders must be monitored closely for severe crises. Glomerulonephritis: Monitoring for kidney inflammation, indicated by changes in urine color or facial swelling. Why Source PEG-FILGRASTIM 6mg from Ernest Oncology? Verified Authenticity: Direct sourcing of high-integrity Peg-Filgrastim with full batch-specific COA and traceability.Cold-Chain Authority: Expert handling of strict $2^circtext{C}$ to $8^circtext{C}$ temperature-controlled export for USA, UK, Australia, and South Africa.Wholesale Solutions: Competitive bulk pricing for hospital groups, specialty pharmacies, and regional distributors.Regulatory Compliance: Every shipment includes GMP certificates and comprehensive B2B documentation to ensure global standards. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383

Etoposide 50mg Injection: Critical Topoisomerase II Inhibition for Combination Chemotherapy Regimens Are you searching for a reliable Etoposide 50mg Injection exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of essential cytotoxic therapies. We maintain an agile and secure supply chain for London (UK), Washington (USA), Canberra (Australia), and South Africa, ensuring that critical oncology medications reach institutional pharmacies with 100% pharmaceutical integrity. Detailed Product Profile: What is Etoposide 50mg Injection? Etoposide 50mg is an intravenous antineoplastic therapy containing the active pharmaceutical ingredient Etoposide (also known as VP-16). This medication is a semi-synthetic derivative of podophyllotoxin and belongs to the class of drugs known as Topoisomerase Inhibitors. It is a cornerstone of many multi-drug chemotherapy protocols, recognized for its efficacy in treating various aggressive hematologic and solid tumors. 1. Therapeutic Indications Small Cell Lung Cancer (SCLC): Often used as first-line therapy in combination with cisplatin or carboplatin. Testicular Cancer: A primary component of the BEP (Bleomycin, Etoposide, Cisplatin) regimen for refractory or advanced germ cell tumors. Lymphomas: Integrated into protocols for Hodgkin’s and Non-Hodgkin’s lymphoma treatment. Acute Myeloid Leukemia (AML): Utilized in induction and consolidation phases for specific leukemia subtypes. Ovarian & Bladder Cancer: Employed in specialized cases where tumors have shown resistance to standard platinum therapies. 2. Mechanism of Action: Cell Cycle Arrest Topoisomerase II Inhibition: It forms a complex with the enzyme Topoisomerase II and DNA. This enzyme is normally responsible for breaking and resealing DNA strands to manage tension during replication. DNA Fragmentation: By inhibiting the resealing process, Etoposide causes permanent breaks in the DNA strands. S and G2 Phase Specificity: It is most active during the S and G2 phases of the cell cycle, preventing the cell from undergoing mitosis and leading to programmed cell death (apoptosis). 3. Administration and Clinical Handling Standard Dosing: Doses are calculated based on Body Surface Area ($mg/m^2$) and vary significantly depending on the protocol and the patient's renal function.Administration: It must be administered via slow intravenous infusion (usually over 30 to 60 minutes). It should never be given by rapid bolus injection as this can cause severe hypotension.Preparation: Must be diluted in 5% Dextrose or 0.9% Sodium Chloride Injection prior to administration.Safety: As a cytotoxic agent, healthcare professionals must follow strict hazardous drug handling protocols during preparation and disposal. Clinical Side Effects & Safety Monitoring Myelosuppression: The dose-limiting side effect is a significant drop in white blood cells (neutropenia) and platelets. Frequent CBC monitoring is essential. Secondary Malignancies: There is a known risk of developing acute leukemia in patients treated with long-term etoposide therapy. Gastrointestinal Health: Nausea, vomiting, and mucositis (mouth sores) are common; pre-medication with antiemetics is standard. Alopecia: Reversible hair loss is observed in a high percentage of patients. Hypotension: Monitoring of blood pressure during the infusion is critical due to the risk of infusion-related low blood pressure. Why Source Etoposide 50mg from Ernest Oncology? Verified Authenticity: Direct sourcing of high-integrity Etoposide with full batch-specific COA and traceability. Logistics Authority: Expert handling of complex cold chain or temperature-controlled export regulations for USA, UK, Australia, and South Africa. Wholesale Solutions: Competitive bulk pricing for hospital groups, specialty pharmacies, and regional distributors. Regulatory Compliance: Every shipment includes GMP certificates and comprehensive B2B documentation to ensure global standards. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383

Ibrulieva 140mg Capsule: Breakthrough Bruton’s Tyrosine Kinase (BTK) Inhibition for B-Cell Malignancies Are you searching for a reliable Ibrulieva 140mg Capsule exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of first-in-class targeted therapies. We maintain an agile and secure supply chain for London (UK), Washington (USA), Canberra (Australia), and South Africa, ensuring that critical hematology-oncology medications reach institutional pharmacies with 100% pharmaceutical integrity. Detailed Product Profile: What is Ibrulieva 140mg? Ibrulieva 140mg is an oral targeted therapy containing the active pharmaceutical ingredient Ibrutinib. Manufactured by Allieva Pharma Pvt Ltd, this 140mg capsule is a potent, irreversible inhibitor of Bruton’s Tyrosine Kinase (BTK). It has transformed the treatment landscape for various B-cell cancers by providing a non-chemotherapy alternative that specifically targets the molecular pathways cancer cells use to survive and multiply. 1. Therapeutic Indications Chronic Lymphocytic Leukemia (CLL) & Small Lymphocytic Lymphoma (SLL): Indicated for both previously untreated and relapsed/refractory patients, including those with high-risk genetic markers like 17p deletion. Mantle Cell Lymphoma (MCL): For adult patients who have received at least one prior therapy. Waldenström’s Macroglobulinemia (WM): A rare type of non-Hodgkin lymphoma; used as monotherapy or in combination with Rituximab. Marginal Zone Lymphoma (MZL): For patients who require systemic therapy and have received at least one prior anti-CD20-based therapy. Chronic Graft Versus Host Disease (cGVHD): For adult and pediatric patients after the failure of one or more lines of systemic therapy. 2. Mechanism of Action: Irreversible Signal Blockade BTK Inhibition: It forms a strong covalent bond with a cysteine residue (Cys-481) in the BTK active site. BTK is a critical signaling molecule for the B-cell antigen receptor (BCR) pathway. Survival Signal Interruption: By blocking BTK, Ibrulieva prevents the activation of downstream survival pathways (like NF-κB and MAPK). Apoptosis and Homed-Inhibition: It inhibits malignant B-cell proliferation, adhesion, and migration to lymphoid tissues, effectively “starving“ the cancer cells of the signals they need to stay alive. 3. Administration and Dosage Management Standard Dosing: Dosing varies by indication. For CLL and WM, the standard dose is 420mg (three 140mg capsules) once daily. For MCL and MZL, the dose is 560mg (four 140mg capsules) once daily. Administration: Should be taken once daily at approximately the same time. Capsules must be swallowed whole with a glass of water. Hydration: Patients are encouraged to maintain adequate hydration while on therapy.Avoidances: Do not open, break, or chew the capsules. Avoid grapefruit and Seville oranges, as they may increase drug levels in the blood. Clinical Side Effects & Safety Monitoring Hemorrhage (Bleeding): Increased risk of bruising and serious bleeding events. Therapy may need to be withheld 3–7 days before and after surgery. Atrial Fibrillation & Flutter: Monitoring for irregular heartbeat, dizziness, or fainting is essential, particularly in patients with cardiac risk factors. Infections: Risk of serious bacterial, viral, or fungal infections. Any fever or chills should be reported immediately. Cytopenias: Potential for Neutropenia and Thrombocytopenia; monthly Complete Blood Counts (CBC) are standard. Hypertension: New or worsening high blood pressure should be monitored and managed clinically. Why Source Ibrulieva 140mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva Pharma’s Ibrulieva with full batch-specific COA and traceability. Logistics Authority: Expert handling of complex import/export regulations for USA, UK, Australia, and South Africa. Wholesale Solutions: Competitive bulk pricing for hospital groups, specialty pharmacies, and regional distributors. Regulatory Compliance: Every shipment includes GMP certificates and comprehensive B2B documentation to ensure global standards. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383

DASALIEVA 50mg Tablet: Next-Generation Tyrosine Kinase Inhibition for Ph+ Leukemia Management Are you searching for a reliable DASALIEVA 50mg Tablet exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced targeted therapies. We maintain an agile and secure supply chain for London (UK), Washington (USA), Canberra (Australia), and South Africa, ensuring that critical oncology medications reach institutional pharmacies with 100% pharmaceutical integrity. Detailed Product Profile: What is DASALIEVA 50mg? DASALIEVA 50mg is an oral targeted therapy containing the active pharmaceutical ingredient Dasatinib. Manufactured by Allieva Pharma Pvt Ltd, this 50mg tablet is a potent, second-generation tyrosine kinase inhibitor (TKI). It is specifically designed to treat cancers characterized by the Philadelphia chromosome (Ph+), offering a high-affinity alternative for patients who are resistant or intolerant to first-generation therapies like Imatinib. 1. Therapeutic Indications Chronic Myeloid Leukemia (CML): Indicated for newly diagnosed adult patients in the chronic phase, as well as those in accelerated or blast crisis phases who have shown resistance to prior therapies. Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Used for adult patients with Ph+ ALL who are resistant or intolerant to prior treatment. Pediatric Oncology: Increasingly used for children with Ph+ CML in the chronic phase. 2. Mechanism of Action: Multi-Pathway Signal Blockade Bcr-Abl Inhibition: It binds to the active and inactive configurations of the Bcr-Abl kinase, the “on-switch“ for leukemia cell production. SRC Family Inhibition: Unlike first-generation TKIs, Dasatinib also inhibits the SRC family of kinases (SRC, LCK, YES, FYN), which are involved in cancer cell migration and survival. High Potency: It is estimated to be significantly more potent than Imatinib in vitro, allowing it to overcome many mutations that cause drug resistance in leukemia cells. 3. Administration and Dosage Management Standard Dosing: The typical dose for chronic phase CML is 100mg once daily (two 50mg tablets). For accelerated or blast phase CML/Ph+ ALL, the dose is often 140mg once daily. Administration: Tablets can be taken with or without food. They must be swallowed whole and never crushed or chewed, as this can affect absorption and increase toxicity risk. Consistency: For optimal therapeutic levels, the medication should be taken at the same time every day. Clinical Side Effects & Safety Monitoring Fluid Retention: Monitoring for pleural effusion (fluid around the lungs) or pericardial effusion. Patients should report any new shortness of breath or dry cough. Hematological Safety: Potential for myelosuppression (lowered blood counts); regular Complete Blood Count (CBC) monitoring is mandatory. Cardiovascular Monitoring: Risk of QT prolongation and pulmonary arterial hypertension (PAH). Gastrointestinal Health: Potential for nausea, diarrhea, and abdominal pain. Drug Interactions: Avoid H2 blockers or Proton Pump Inhibitors (PPIs) as they can significantly reduce the absorption of Dasatinib. Why Source DASALIEVA 50mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva Pharma’s DASALIEVA with full batch-specific COA and traceability. Logistics Authority: Expert handling of complex import/export regulations for USA, UK, Australia, and South Africa. Wholesale Solutions: Competitive bulk pricing for hospital groups, specialty pharmacies, and regional distributors. Regulatory Compliance: Every shipment includes GMP certificates and comprehensive B2B documentation to ensure global standards. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383

CRIZLIEVA 250mg Tablet: Targeted ALK and ROS1 Inhibition for Advanced Non-Small Cell Lung Cancer Are you searching for a reliable CRIZLIEVA 250 mg tablet exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced tyrosine kinase inhibitors. We maintain an agile and secure supply chain for London (UK), Washington (USA), Canberra (Australia), and South Africa, ensuring that critical oncology medications reach institutional pharmacies with 100% pharmaceutical integrity. Detailed Product Profile: What is CRIZLIEVA 250mg? CRIZLIEVA 250mg is an oral targeted therapy containing the active pharmaceutical ingredient Crizotinib. Manufactured by Allieva Pharma Pvt Ltd, this 250mg tablet is a first-in-class receptor tyrosine kinase inhibitor. It is specifically designed to treat patients with non-small cell lung cancer (NSCLC) that is driven by specific genetic alterations, offering a precision medicine approach that is more effective than traditional chemotherapy for these subtypes. 1. Therapeutic Indications ALK-Positive Metastatic NSCLC: Indicated for patients whose tumors are positive for anaplastic lymphoma kinase (ALK) as detected by an approved test. ROS1-Positive Metastatic NSCLC: Specifically utilized for patients with metastatic non-small cell lung cancer whose tumors are ROS1-positive. Advanced Disease Management: Used as both a first-line therapy and for patients who have progressed on previous treatments, helping to shrink or slow the growth of tumors. 2. Mechanism of Action: Molecular Signal Disruption Kinase Inhibition: It inhibits the C-Met/Hepatocyte Growth Factor Receptor (HGFR), ROS1, and ALK tyrosine kinases. Targeting Mutations: In ALK-positive or ROS1-positive cancers, these proteins are overactive, sending continuous “grow“ signals to the cells. Crizotinib binds to these proteins and “turns off“ the signal. Halting Proliferation: By interrupting these pathways, the medication prevents the survival and proliferation of malignant cells, often leading to significant tumor regression. 3. Administration and Dosage Management Standard Dosing: The typical recommended dose is 250mg taken orally twice daily. Administration: Can be taken with or without food. Tablets must be swallowed whole; do not crush, dissolve, or open the capsules. Monitoring: Dosage may be adjusted by an oncologist based on individual safety and tolerability. Clinical Side Effects & Safety Monitoring Hepatotoxicity: Potential for drug-induced liver injury; periodic Liver Function Tests (LFTs) are mandatory. Ocular Effects: Visual disturbances (such as light flashes or blurred vision) are common but often transient. Pneumonitis: Rare but serious risk of severe or life-threatening drug-related lung inflammation. Cardiovascular Safety: Monitoring for QT interval prolongation and bradycardia (slow heart rate). Gastrointestinal Health: Nausea, vomiting, and diarrhea are common; hydration and supportive care are recommended. Why Source CRIZLIEVA 250mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva Pharma’s CRIZLIEVA with full batch-specific COA and traceability. Logistics Authority: Expert handling of complex import/export regulations for USA, UK, Australia, and South Africa. Wholesale Solutions: Competitive bulk pricing for hospital groups, specialty pharmacies, and regional distributors. Regulatory Compliance: Every shipment includes GMP certificates and comprehensive B2B documentation to ensure global standards. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383

MEGESLIEVA 160mg Tablet: Advanced Progestin Therapy for Oncology and Cachexia Management Are you searching for a reliable MEGESLIEVA 160mg Tablet exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of high-potency hormonal therapies. We maintain an agile and secure supply chain for London (UK), Washington (USA), Canberra (Australia), and South Africa, ensuring that critical oncology medications reach institutional pharmacies with 100% pharmaceutical integrity. Detailed Product Profile: What is MEGESLIEVA 160mg? MEGESLIEVA 160mg is an oral hormonal therapy containing the active pharmaceutical ingredient Megestrol Acetate. Manufactured by Allieva Pharma Pvt Ltd, this 160mg tablet is a synthetic derivative of the naturally occurring steroid hormone progesterone. It is widely utilized in oncology for its progestational effects to treat hormone-dependent cancers and as a metabolic stimulant to manage severe weight loss and appetite loss in chronic illnesses. 1. Therapeutic Indications Breast Cancer: Palliative treatment of advanced breast cancer in postmenopausal women, especially those with hormone receptor-positive tumors. Endometrial Cancer: Indicated for the palliative management of advanced, recurrent, or metastatic endometrial carcinoma. Anorexia and Cachexia: Treatment of significant weight loss, muscle wasting, and loss of appetite associated with advanced cancer or HIV/AIDS. Hormonal Regulation: Used in specific clinical cases to manage abnormal uterine bleeding or as part of secondary hormonal therapy protocols. 2. Mechanism of Action: Hormonal and Metabolic Modulation Antineoplastic Effect: In breast and endometrial cancers, it inhibits the pituitary-ovarian axis, reducing the production of luteinizing hormone (LH). It also directly modulates estrogen receptors, making the tumor environment less favorable for hormone-dependent growth. Orexigenic (Appetite Stimulant) Effect: The exact mechanism for weight gain is complex but involves the stimulation of the hypothalamic appetite center and the modulation of cytokines (like IL-1, IL-6, and TNF-alpha) that contribute to muscle wasting and weight loss. Metabolic Shift: It promotes an increase in body fat and body cell mass, helping patients maintain physical strength during aggressive treatments. 3. Administration and Dosage Management Standard Dosing: For breast cancer, the typical dose is 160mg once daily. For anorexia/cachexia, doses may range from 400mg to 800mg per day based on medical guidance. Administration: Can be taken with or without food. Tablets should be swallowed whole with a glass of water. Consistency: It is essential to take the medication at the same time every day to maintain steady hormonal levels. Clinical Side Effects & Safety Monitoring Thromboembolic Risks: Increased risk of blood clots (DVT or pulmonary embolism); patients with a history of thrombophlebitis require extreme caution. Weight Gain: While often a desired effect in cachexia, it should be monitored to ensure it is not due to fluid retention (edema). Adrenal Suppression: Long-term use can affect the adrenal glands; patients should not stop the medication abruptly without medical advice. Glucose Tolerance: Potential for new-onset diabetes or exacerbation of existing diabetes; blood sugar monitoring is recommended. Hormonal Changes: Potential for breakthrough bleeding, impotence, or mood changes. Why Source MEGESLIEVA 160mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva Pharma’s MEGESLIEVA with full batch-specific COA and traceability. Logistics Authority: Expert handling of complex import/export regulations for USA, UK, Australia, and South Africa. Wholesale Solutions: Competitive bulk pricing for hospital groups, specialty pharmacies, and regional distributors. Regulatory Compliance: Every shipment includes GMP certificates and comprehensive B2B documentation to ensure global standards. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383

Geflieva 250mg Tablet: Precision EGFR Inhibition for Advanced Non-Small Cell Lung Cancer Are you searching for a reliable Geflieva 250mg Tablet exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of targeted tyrosine kinase inhibitors. We maintain an agile and secure supply chain for London (UK), Washington (USA), Canberra (Australia), and South Africa, ensuring that critical oncology medications reach institutional pharmacies with 100% pharmaceutical integrity. Detailed Product Profile: What is Geflieva 250mg? Geflieva 250mg is an oral targeted therapy containing the active pharmaceutical ingredient Gefitinib. Manufactured by Allieva Pharma Pvt Ltd, this 250mg tablet is a potent EGFR (Epidermal Growth Factor Receptor) tyrosine kinase inhibitor. It is specifically designed to treat patients with non-small cell lung cancer (NSCLC) that harbors specific activating mutations, offering a targeted alternative to traditional systemic chemotherapy. 1. Therapeutic Indications Metastatic Non-Small Cell Lung Cancer (NSCLC): Indicated as first-line treatment for patients whose tumors have specific EGFR mutations (such as exon 19 deletions or exon 21 L858R substitution mutations). Maintenance Therapy: Used in specific clinical settings to prevent disease progression in patients who have responded to initial platinum-based chemotherapy. Second-line Treatment: Utilized for patients whose cancer has progressed despite receiving prior chemotherapy protocols. 2. Mechanism of Action: Targeted Molecular Blockade EGFR Inhibition: It binds to the adenosine triphosphate (ATP) binding site of the enzyme tyrosine kinase associated with the Epidermal Growth Factor Receptor (EGFR). Signal Disruption: By blocking this site, Geflieva interrupts the signaling pathways (like Ras/Raf/MAPK) that are responsible for cancer cell survival, proliferation, and angiogenesis. Selective Cytotoxicity: Because it targets a specific receptor often overexpressed in lung cancer cells, it effectively inhibits tumor growth while sparing many types of healthy cells. 3. Administration and Dosage Management Standard Dosing: The typical recommended dose is one 250mg tablet taken once daily. Administration: Can be taken with or without food. Tablets should be swallowed whole; however, for patients with swallowing difficulties, the tablet can be dispersed in non-carbonated drinking water. Duration: Treatment is generally continued as long as the patient derives clinical benefit without experiencing unacceptable toxicity. Clinical Side Effects & Safety Monitoring Dermatological Safety: Skin rash (acneform) and dry skin are very common; monitoring for severe bullous or exfoliative conditions is required. Gastrointestinal Health: Potential for diarrhea, nausea, and vomiting. Persistent diarrhea may require clinical intervention or dose adjustment. Hepatotoxicity: Periodic Liver Function Tests (LFTs) are recommended as Gefitinib can cause elevations in liver enzymes. Pulmonary Monitoring: Rare but serious risk of Interstitial Lung Disease (ILD). Patients must report new or worsening shortness of breath or cough immediately. Ocular Health: Patients should be monitored for signs of keratitis or corneal erosion. Why Source Geflieva 250mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva Pharma’s Geflieva with full batch-specific COA and traceability. Logistics Authority: Expert handling of complex import/export regulations for USA, UK, Australia, and South Africa. Wholesale Solutions: Competitive bulk pricing for hospital groups, specialty pharmacies, and regional distributors. Regulatory Compliance: Every shipment includes GMP certificates and comprehensive B2B documentation to ensure global standards. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383

Melieva 2mg Tablet: Targeted Alkylating Therapy for Multiple Myeloma and Advanced Malignancies Are you searching for a reliable Melieva 2mg Tablet exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of critical cytotoxic therapies. We maintain an agile and secure supply chain for London (UK), Washington (USA), Canberra (Australia), and South Africa, ensuring that life-saving oncology medications reach institutional pharmacies with 100% pharmaceutical integrity. Detailed Product Profile: What is Melieva 2mg? Melieva 2mg is an oral antineoplastic therapy containing the active pharmaceutical ingredient Melphalan. Manufactured by Allieva Pharma Pvt Ltd, this 2mg tablet belongs to the class of medications known as Alkylating Agents. It is a nitrogen mustard derivative specifically designed to treat cancers of the blood and bone marrow, serving as a pillar in hematological oncology for decades. 1. Therapeutic Indications Multiple Myeloma: Often used in combination with other agents (like Prednisone) for the palliative treatment of patients with multiple myeloma. Ovarian Adenocarcinoma: Indicated for the treatment of non-resectable epithelial ovarian cancer. Polycythemia Vera: Utilized to control the overproduction of red blood cells in specific patient cases. Advanced Breast Cancer: Occasionally used in palliative protocols for advanced stages of the disease. Conditioning Therapy: In higher dose protocols, it is used as a conditioning treatment before bone marrow or stem cell transplants. 2. Mechanism of Action: DNA Cross-Linking Alkylation of DNA: The medication attaches an alkyl group to the DNA of cancer cells. Interstrand Cross-linking: It creates chemical bonds between the two strands of the DNA double helix. Inhibition of Replication: By “locking“ the DNA strands together, the cancer cell can no longer replicate its genetic material or repair itself. Cell Cycle Non-Specific: Unlike some therapies, Melphalan can attack cancer cells at various stages of their growth cycle, leading to effective tumor mass reduction. 3. Administration and Dosage Management Standard Dosing: Dosage is highly individualized based on the patient's body surface area (BSA) and blood counts. Administration: It is generally recommended to take Melieva on an empty stomach (1 hour before or 2 hours after meals) to ensure consistent absorption. Handling: As a potent cytotoxic drug, the tablets should not be crushed or broken. Caregivers should handle the medication with caution. Clinical Side Effects & Safety Monitoring Bone Marrow Suppression: The primary side effect is a decrease in white blood cells (leukopenia) and platelets (thrombocytopenia). Frequent blood counts are mandatory. Gastrointestinal Health: Potential for nausea, vomiting, and mouth sores (mucositis). Secondary Malignancies: Long-term use of alkylating agents has been associated with an increased risk of secondary leukemias. Pulmonary Monitoring: Rare cases of pulmonary fibrosis have been reported; patients should report any persistent cough or breathing difficulties. Renal Function: Patients with impaired kidney function require careful dose adjustment to avoid toxicity. Why Source Melieva 2mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva Pharma’s Melieva with full batch-specific COA and traceability. Logistics Authority: Expert handling of complex import/export regulations for USA, UK, Australia, and South Africa. Wholesale Solutions: Competitive bulk pricing for hospital groups, specialty pharmacies, and regional distributors. Regulatory Compliance: Every shipment includes GMP certificates and comprehensive B2B documentation to ensure global standards. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383

Regolieva 40mg Tablet: Multi-Kinase Inhibition for Refractory Colorectal, GIST, and Hepatic Malignancies Are you searching for a reliable Regolieva 40mg Tablet exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced multi-kinase inhibitors. We maintain an agile and secure supply chain for London (UK), Washington (USA), Canberra (Australia), and South Africa, ensuring that critical oncology medications reach institutional pharmacies with 100% pharmaceutical integrity. Detailed Product Profile: What is Regolieva 40mg? Regolieva 40mg is an oral targeted therapy containing the active pharmaceutical ingredient Regorafenib. Manufactured by Allieva Pharma Pvt Ltd, this 40mg tablet is a potent multi-kinase inhibitor designed to attack cancer on multiple fronts. It is primarily utilized as a salvage therapy for patients with advanced cancers that have progressed despite standard treatments, providing a vital line of defense in complex oncology cases. 1. Therapeutic Indications Metastatic Colorectal Cancer (mCRC): For patients previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. Gastrointestinal Stromal Tumors (GIST): For patients with locally advanced, unresectable, or metastatic GIST who were previously treated with imatinib mesylate and sunitinib malate. Hepatocellular Carcinoma (HCC): For patients with liver cancer who have been previously treated with sorafenib. 2. Mechanism of Action: Triple-Action Multi-Kinase Inhibition Anti-Angiogenesis: It inhibits VEGFR1, VEGFR2, and VEGFR3, effectively “starving“ the tumor by blocking the growth of new blood vessels. Oncogenesis Inhibition: It targets various kinases (like KIT, RET, and RAF-1) that drive the uncontrolled growth and proliferation of cancer cells. Tumor Microenvironment Regulation: By inhibiting PDGFR and FGFR, it disrupts the signaling between the tumor and its surrounding tissue, slowing down the spread and invasion of malignant cells. 3. Administration and Dosage Management Standard Dosing: The typical dose is 160mg (four 40mg tablets) taken once daily for the first 21 days of each 28-day cycle. Administration: Must be taken after a low-fat meal (containing less than 30% fat) to ensure consistent absorption. Consistency: Tablets must be swallowed whole with water. Do not crush or chew. It should be taken at the same time each day. Clinical Side Effects & Safety Monitoring Hepatotoxicity: Potential for severe drug-induced liver injury; Liver Function Tests (LFTs) are mandatory before and during treatment. Hand-Foot Skin Reaction (HFSR): Redness, pain, or swelling on the palms and soles is common; proactive dermatological care is recommended. Hypertension: Blood pressure often increases early in the cycle and must be monitored weekly. Gastrointestinal Health: Monitoring for severe diarrhea, nausea, and weight loss. Bleeding Risks: Due to its anti-angiogenic properties, patients should be monitored for internal or external bleeding events. Why Source Regolieva 40mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva Pharma’s Regolieva with full batch-specific COA and traceability. Logistics Authority: Expert handling of complex import/export regulations for USA, UK, Australia, and South Africa. Wholesale Solutions: Competitive bulk pricing for hospital groups, specialty pharmacies, and regional distributors. Regulatory Compliance: Every shipment includes GMP certificates and comprehensive B2B documentation to ensure global standards. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383

Acalieva 100mg Capsule: Next-Generation BTK Inhibition for Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Are you searching for a reliable Acalieva 100mg Capsule exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of highly selective targeted therapies. We maintain an agile and secure supply chain for London (UK), Washington (USA), Canberra (Australia), and South Africa, ensuring that critical hematology-oncology medications reach institutional pharmacies with 100% pharmaceutical integrity. Detailed Product Profile: What is Acalieva 100mg? Acalieva 100mg is an oral targeted therapy containing the active pharmaceutical ingredient Acalabrutinib. Manufactured by Allieva Pharma Pvt Ltd, this 100mg capsule is a second-generation, highly selective Bruton’s Tyrosine Kinase (BTK) inhibitor. It represents a significant advancement in the treatment of B-cell malignancies, offering improved selectivity and a potentially better safety profile compared to first-generation BTK inhibitors. 1. Therapeutic Indications Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL): Indicated as a first-line treatment or for patients who have received at least one prior therapy. Mantle Cell Lymphoma (MCL): Used for adult patients who have received at least one prior therapy for their disease. Relapsed or Refractory B-cell Malignancies: Providing a potent oral option for patients whose cancer has returned after initial treatments. 2. Mechanism of Action: Selective BTK Blockade BTK Inhibition: It forms a covalent bond with a cysteine residue (Cys481) in the BTK active site. BTK is a signaling molecule of the B-cell antigen receptor (BCR) pathway. Interrupting Growth Signals: By blocking BTK, Acalieva inhibits the signaling that leads to B-cell proliferation, trafficking, chemotaxis, and adhesion. High Selectivity: As a second-generation inhibitor, it is designed to be more selective for BTK over other kinases (like EGFR or ITK), which helps in reducing off-target side effects. 3. Administration and Dosage Management Standard Dosing: The typical recommended dose is 100mg taken orally twice daily (approximately 12 hours apart). Administration: Capsules should be swallowed whole with water. They can be taken with or without food. Acid-Reducing Agents: Patients should exercise caution with Proton Pump Inhibitors (PPIs), as they can affect the absorption of the medication. Consult an oncologist for timing with H2-receptor antagonists or antacids. Clinical Side Effects & Safety Monitoring Hematological Safety: Potential for Cytopenias (anemia, neutropenia, or thrombocytopenia). Periodic Complete Blood Counts (CBC) are necessary. Cardiovascular Health: Monitoring for Atrial Fibrillation and hypertension, though risks may be lower compared to earlier BTK inhibitors. Hemorrhage Risks: Patients should be monitored for signs of bleeding, especially those on concurrent antiplatelet or anticoagulant therapy. Infection Control: Increased susceptibility to opportunistic infections; patients should report any fever or signs of illness immediately. Headache: A common side effect often reported at the start of treatment, which usually subsides over time. Why Source Acalieva 100mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva Pharma’s Acalieva with full batch-specific COA and traceability. Logistics Authority: Expert handling of complex import/export regulations for USA, UK, Australia, and South Africa. Wholesale Solutions: Competitive bulk pricing for hospital groups, specialty pharmacies, and regional distributors. Regulatory Compliance: Every shipment includes GMP certificates and comprehensive B2B documentation to ensure global standards. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383

Erlolieva 150mg Tablet: Targeted Epidermal Growth Factor Receptor (EGFR) Inhibition for Advanced Oncology Are you searching for a reliable Erlolieva 150 mg tablet exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of targeted tyrosine kinase inhibitors. We maintain an agile and secure supply chain for London (UK), Washington (USA), Canberra (Australia), and South Africa, ensuring that critical oncology medications reach institutional pharmacies with 100% pharmaceutical integrity. Detailed Product Profile: What is Erlolieva 150mg? Erlolieva 150mg is an oral targeted therapy containing the active pharmaceutical ingredient Erlotinib. Manufactured by Allieva Pharma Pvt Ltd, this 150mg tablet belongs to the class of medications known as EGFR Tyrosine Kinase Inhibitors (TKIs). It is a cornerstone treatment for patients with specific genetic mutations in non-small cell lung cancer and advanced pancreatic malignancies, designed to interrupt the molecular signals that drive cancer progression. 1. Therapeutic Indications Metastatic Non-Small Cell Lung Cancer (NSCLC): Used as first-line, maintenance, or second-line therapy for patients whose tumors have specific EGFR mutations (Exon 19 deletions or Exon 21 L858R substitution). Advanced Pancreatic Cancer: Used in combination with Gemcitabine for the treatment of patients with locally advanced, unresectable, or metastatic pancreatic cancer. Maintenance Therapy: Indicated for patients with locally advanced or metastatic NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. 2. Mechanism of Action: Reversible Receptor Blockade EGFR Targeting: It targets the Epidermal Growth Factor Receptor (EGFR), a protein on the surface of cells that normally helps them grow and divide. In many cancer cells, this receptor is overactive or mutated. ATP Competition: Erlotinib binds reversibly to the Adenosine Triphosphate (ATP) binding site of the receptor's intracellular tyrosine kinase domain. Signal Interruption: By blocking ATP, it prevents the phosphorylation process required to send growth signals to the nucleus, effectively stalling tumor cell proliferation and inducing apoptosis (programmed cell death). 3. Administration and Dosage Management Standard Dosing: The typical dose is 150 mg once daily for NSCLC and 100 mg once daily for pancreatic cancer (in combination with gemcitabine). Timing: Must be taken on an empty stomach, at least 1 hour before or 2 hours after a meal. Food significantly increases the bioavailability, which can lead to increased toxicity. Storage: Keep at room temperature, away from moisture and direct heat, in its original packaging. Clinical Side Effects & Safety Monitoring Dermatological Safety: An “acne-like“ rash is very common and often indicates the drug is working. Patients should also monitor for dry skin and nail changes. Gastrointestinal Health: Potential for diarrhea, nausea, and stomatitis. Severe diarrhea may require dose interruption or hydration therapy. Pulmonary Monitoring: Rare but serious risk of Interstitial Lung Disease (ILD). Patients should report any new or worsening cough or shortness of breath. Ocular Safety: Monitoring for corneal ulceration or perforation, especially in patients with a history of dry eyes. Drug Interactions: Avoid proton pump inhibitors (PPIs) and smoking, as both can significantly reduce the concentration of erlotinib in the blood. Why Source Erlolieva 150mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva Pharma’s Erlolieva with full batch-specific COA and traceability. Logistics Authority: Expert handling of complex import/export regulations for the USA, UK, Australia, and South Africa. Wholesale Solutions: Competitive bulk pricing for hospital groups, specialty pharmacies, and regional distributors. Regulatory Compliance: Every shipment includes GMP certificates and comprehensive B2B documentation to ensure global standards. 📞 Contact Ernest Oncology—Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383

Lapalieva 250mg Tablet: Dual Tyrosine Kinase Inhibition for HER2-Positive Advanced Breast Cancer Are you searching for a reliable Lapalieva 250mg Tablet exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of targeted kinase inhibitors. We maintain an agile and secure supply chain for London (UK), Washington (USA), Canberra (Australia), and South Africa, ensuring that critical oncology medications reach institutional pharmacies with 100% pharmaceutical integrity. Detailed Product Profile: What is Lapalieva 250mg? Lapalieva 250mg is an oral targeted therapy containing the active pharmaceutical ingredient Lapatinib. Manufactured by Allieva Pharma Pvt Ltd, this 250mg tablet is a potent dual tyrosine kinase inhibitor. It is specifically engineered to target cancers that overexpress the HER2 (Human Epidermal Growth Factor Receptor 2) protein, providing a critical treatment option for patients with advanced or metastatic breast cancer. 1. Therapeutic Indications HER2-Positive Advanced Breast Cancer: Used in combination with Capecitabine for patients who have received prior therapy including an anthracycline, a taxane, and Trastuzumab. Hormone Receptor-Positive Metastatic Breast Cancer: Used in combination with an aromatase inhibitor (like Letrozole) for postmenopausal women for whom hormonal therapy is indicated. Metastatic Progression: Indicated for tumors that have progressed despite intravenous targeted therapies, offering an oral alternative for systemic control. 2. Mechanism of Action: Intracellular Dual Blockade Dual Inhibition: Unlike some therapies that only target the outside of the cell, Lapatinib penetrates the cell membrane to inhibit both EGFR (ErbB1) and HER2 (ErbB2) receptors. Signal Interruption: By binding to the intracellular ATP-binding domain of these kinases, it blocks the phosphorylation and subsequent signaling pathways (like MAPK and PI3K) that lead to cell proliferation. Tumor Growth Arrest: This dual blockade effectively shuts down the “growth commands“ of the cancer cell, leading to reduced tumor size and slowing the spread of the disease. 3. Administration and Dosage Management Standard Dosing: The typical dose for HER2-positive breast cancer is 1,250 mg (five 250mg tablets) taken once daily for 21 days in combination with Capecitabine. Administration: Lapalieva must be taken at least one hour before or one hour after a meal. Taking it with food significantly changes the absorption levels. Consistency: The tablets must be swallowed whole; do not crush or chew. All five tablets should be taken at the same time each day. Clinical Side Effects & Safety Monitoring Gastrointestinal Health: Diarrhea is a very common side effect and can be severe; early intervention with anti-diarrheal medication is often required. Hepatotoxicity: Potential for liver toxicity; Liver Function Tests (LFTs) should be monitored every 4 to 6 weeks during treatment. Cardiac Function: Lapatinib may decrease Left Ventricular Ejection Fraction (LVEF). Heart function (ECHO or MUGA scans) should be checked before and during therapy. Dermatological Safety: Potential for “acneform“ rash or dry skin. Patients should report any significant skin changes immediately. QT Prolongation: Monitoring for heart rhythm changes is advised, especially if taken with other medications that affect the heart. Why Source Lapalieva 250mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva Pharma’s Lapalieva with full batch-specific COA and traceability. Logistics Authority: Expert handling of complex import/export regulations for USA, UK, Australia, and South Africa. Wholesale Solutions: Competitive bulk pricing for hospital groups, specialty pharmacies, and regional distributors. Regulatory Compliance: Every shipment includes GMP certificates and comprehensive B2B documentation to ensure global standards. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383